Balyasny Asset Management L.P. Makes New $8.15 Million Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Balyasny Asset Management L.P. bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 248,038 shares of the biopharmaceutical company's stock, valued at approximately $8,151,000. Balyasny Asset Management L.P. owned approximately 0.43% of Agios Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth about $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $53,000. Sterling Capital Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV lifted its holdings in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after purchasing an additional 2,338 shares during the period.

Analyst Ratings Changes

AGIO has been the subject of a number of research reports. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. Finally, Scotiabank decreased their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Trading Down 1.4%

AGIO stock traded down $0.40 during midday trading on Tuesday, hitting $28.74. 511,844 shares of the company's stock were exchanged, compared to its average volume of 695,931. The business has a 50-day simple moving average of $29.14 and a two-hundred day simple moving average of $37.06. The stock has a market capitalization of $1.66 billion, a PE ratio of 2.53 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. The trade was a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.